The DEPO chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the DEPO chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The DEPO stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View DEPO Detailed Price Forecast - CNN Money||View DEPO Detailed Summary - Google Finance|
|View DEPO Detailed Summary - Yahoo! Finance||View DEPO Stock Research & Analysis - Zacks.com|
|View DEPO Trends & Analysis - Trade-Ideas||View DEPO Major Holders - Barrons|
|View DEPO Call Transcripts - NASDAQ||View DEPO Breaking News & Analysis - Seeking Alpha|
|View DEPO Annual Report - CompanySpotlight.com||View DEPO OTC Short Report - OTCShortReport.com|
|View DEPO Fundamentals - TradeKing||View DEPO SEC Filings - Bar Chart|
|View Historical Prices for DEPO - The WSJ||View Performance/Total Return for DEPO - Morningstar|
|View the Analyst Estimates for DEPO - MarketWatch||View the Earnings History for DEPO - CNBC|
|View the DEPO Earnings - StockMarketWatch||View DEPO Buy or Sell Recommendations - MacroAxis|
|View the DEPO Bullish Patterns - American Bulls||View DEPO Short Pain Metrics - ShortPainBot.com|
|View DEPO Stock Mentions - StockTwits||View DEPO Stock Mentions - PennyStockTweets|
|View DEPO Stock Mentions - Twitter||View DEPO Investment Forum News - Investor Hub|
|View DEPO Stock Mentions - Yahoo! Message Board||View DEPO Stock Mentions - Seeking Alpha|
|View Insider Transactions for DEPO - SECform4.com||View Insider Transactions for DEPO - Insider Cow|
|View DEPO Major Holdings Summary - CNBC||View Insider Disclosure for DEPO - OTC Markets|
|View Insider Transactions for DEPO - Yahoo! Finance||View Institutional Holdings for DEPO - NASDAQ|
|View DEPO Stock Insight & Charts - FinViz.com||View DEPO Investment Charts - StockCharts.com|
|View DEPO Stock Overview & Charts - BarChart||View DEPO User Generated Charts - Trading View|
Depomed Inc. Announces Corporate Name Change to Assertio Therapeutics, Inc.
Posted on Wednesday August 15, 2018
Assertio Therapeutics, Inc. (NASDAQ:ASRT), a leading specialty pharmaceutical company committed to advancing patient care, has announced that its corporate name change from “Depomed, Inc.” to “Assertio Therapeutics, Inc.” became effective at 11:59 p.m. ET yesterday, August 14, 2018. In connection with the name change, the Company’s common stock will begin trading under a new ticker symbol “ASRT” and a new CUSIP number, 04545L 107, at the opening of trading today, August 15, 2018. “Over the last several years, we have taken strategic actions to transition the Company to focus on our neurology, orphan and specialty medicines,” said Arthur Higgins, President and CEO of Assertio Therapeutics, Inc. “As we’ve transformed, it has become clear that the name Depomed no longer accurately reflects the business we’re in today or the future direction in which we’re headed.
See what the IHS Markit Score report has to say about Depomed Inc.
Posted on Saturday August 11, 2018
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Depomed: 2Q Earnings Snapshot
Posted on Wednesday August 08, 2018
The Newark, California-based company said it had a loss of 33 cents per share. Earnings, adjusted for non-recurring costs and stock option expense, were 19 cents per share. The results exceeded Wall Street ...
Depomed Announces Second-Quarter 2018 Financial Results
Posted on Wednesday August 08, 2018
--Raises Full-Year Earnings and Adjusted EBITDA Guidance Range and Lowers Full-Year Net Sales Guidance Range for the Neurology Franchise--. --Confirms Regulatory Plan to File for FDA Approval of Cosyntropin ...